Williams Cancer Institute

TNF inhibitors

TNF inhibitors


In a study published in Nature, May 2, 2019, Perez-Ruiz, et al., described how the prophylactic use of TNF blockersincreased the effectiveness of the combination of CTLA-4 and PD-1 immunotherapy, while at the same time reducingautoimmune colitis and hepatitis. Keep in mind, this is in a mouse model, but is still promising. In this study they used the TNF inhibitor etanercept (Enbrel). They showed that notonly were adverse autoimmune effects reduced, but also there was increased T cell infiltration in the tumor that resulted inincreased complete tumor rejection. Overall this sounds like a “win-win” situation. Though clearly we need further studies, since etanercept is FDA-approved it could easily be adopted as an off-label treatment.

Reference: Jason R. Williams, 15 Oct 2019, The Immunotherapy Revolution: The Best New Hope For Saving Cancer Patients’ Lives, https://williamscancerinstitute.com/the-immunotherapy-revolution

Related Posts

Blog 23 de mayo de 2024
Blog 21 de mayo de 2024
Blog 20 de mayo de 2024
1 2 3 111